Veeva Systems Inc. — Form 10-Q summary
Reporting period: Third quarter and first nine months of fiscal 2023, ended October 31, 2022; comparisons are with the corresponding 2021 periods. Veeva provides cloud software, data, analytics, and services, primarily to the life sciences industry. Figures are in U.S. dollars.
Financial results and liquidity
| Metric | Q3 FY2023 | Q3 FY2022 | Nine months FY2023 | Nine months FY2022 |
|---|---|---|---|---|
| Revenue | $552.4 million (+16%) | $476.1 million | $1,591.7 million (+17%) | $1,365.3 million |
| Subscription revenue | $441.6 million (+16%) | $380.7 million | $1,272.9 million (+17%) | $1,088.3 million |
| Gross margin | 72%, versus 73% | 73% | 72%, versus 73% | 73% |
| Operating income | $121.4 million | $132.7 million | $350.2 million | $385.8 million |
| Net income | $108.5 million | $105.9 million | $299.2 million | $330.3 million |
| Diluted earnings per share | $0.67 | $0.65 | $1.84 | $2.03 |
| Operating cash flow | $142.7 million | $113.0 million | $717.1 million | $710.4 million |
Q3 operating income declined about 9% despite revenue growth, as operating expenses rose 30% to $277.0 million. Research and development expense increased 32%, sales and marketing 30%, and general and administrative 24%. Stock-based compensation was $93.2 million for the quarter and $256.4 million for the nine-month period. Q3 net income rose about 2%; nine-month net income declined about 9%, with the prior-year period benefiting from greater excess tax benefits related to employee equity awards.
As of October 31, cash and cash equivalents were $865.2 million and short-term investments were $2.157 billion, totaling approximately $3.02 billion. The company reported no debt in the supplied financial statements; lease liabilities totaled approximately $61.9 million. Nine-month investing cash outflow of $968.4 million primarily reflected net purchases of short-term investments. The company said operating cash flow is seasonally strongest in the first fiscal quarter and expected fourth-quarter operating cash flow to be substantially lower than the first nine months’ contribution.
Short-term investments had $49.7 million of gross unrealized losses at quarter end. Management reported no credit-loss allowance, citing investment credit quality and its intent and ability to hold securities until recovery of cost basis. An immediate 100-basis-point rate increase was estimated to reduce portfolio market value by $23 million.
Business changes and outlook
- Subscription revenue remained 80% of total revenue. R&D Solutions generated $202.3 million of Q3 subscription revenue, up from $157.6 million; Commercial Solutions generated $239.3 million, up from $223.2 million. Management expects R&D Solutions to continue increasing as a share of revenue.
- Management expects revenue and subscription revenue to continue growing in the remainder of fiscal 2023, but says year-over-year growth will be pressured by foreign exchange, lower funding or spending in parts of the customer base, and increased scrutiny of potential projects. No specific numerical revenue outlook is provided in the supplied filing text.
- Remaining performance obligations for subscription contracts were approximately $1.189 billion at October 31, 2022; about 73% was expected to be recognized over the next 12 months. Management cautions that deferred revenue and calculated billings can vary with billing terms and renewal timing and may not reliably indicate future revenue.
- Beginning February 1, 2023, Veeva plans to add a termination-for-convenience right to all master subscription agreements governing multi-year orders. Management expects the change to reduce revenue in fiscal 2024 for certain existing multi-year orders by changing revenue-recognition timing.
- For new or renewed order forms entered after April 1, 2023, Veeva plans an annual price adjustment equal to the lower of 4% or the specified prior-August U.S. Consumer Price Index.
- Management expects expenses to rise with hiring and product investment. It also expects additional general and administrative expense related to ongoing litigation and payroll taxes associated with the CEO’s planned option exercise. That exercise, expected between December 5, 2022 and March 8, 2023, is expected to significantly reduce the effective tax rate in the period it occurs.
Risks, contingencies, and notable items
- CRM platform migration: Veeva plans to migrate its multichannel CRM applications from Salesforce’s platform to Veeva Vault, targeting early adopters in 2024 and all customers in 2025. The Salesforce agreement ends September 1, 2025, with a wind-down period through September 1, 2030; customers must migrate by the latter date. Execution problems or customer attrition could materially affect results.
- Customer and market conditions: The company cites heightened enterprise project scrutiny, reduced funding in some early-stage life sciences segments, and expected reductions in life-sciences sales-representative headcount—most expected by the end of fiscal 2023, with reductions continuing into fiscal 2024—as potential pressure on demand, including for CRM.
- Foreign exchange and macroeconomic exposure: Currency movements reduced reported revenue in the first three quarters of fiscal 2023; management expects further revenue pressure for the fiscal year. Inflation, interest rates, COVID-19 developments, and geopolitical disruption, including the war in Ukraine, are also identified as risks.
- Litigation: IQVIA litigation remains ongoing, with expert discovery expected to finish in May 2023. Veeva says it cannot meaningfully estimate a potential gain or loss. A separate Medidata case was resolved in Veeva’s favor by judgment in July 2022; Medidata’s stated intent to appeal remained pending. The company also describes ongoing California litigation involving non-compete and related claims.
- Other exposure: Key risks include cybersecurity and privacy, dependence on third-party infrastructure and data providers, competition, customer concentration, regulatory compliance, and the planned CRM migration. Management reported disclosure controls were effective as of October 31, 2022 and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether revenue growth, customer spending, and project approvals track management’s qualitative outlook amid foreign-exchange and macroeconomic pressure.
- How the multi-year contract termination right affects fiscal 2024 revenue recognition and the interpretation of remaining performance obligations.
- Progress, timing, customer adoption, and costs of the Salesforce-to-Vault CRM migration, including any changes to the stated 2024–2030 milestones.
- Whether rising compensation, stock-based compensation, professional-services costs, and legal expenses continue to pressure operating margins.
- Developments in IQVIA and other litigation, including any change in potential exposure or recoveries; the filing does not provide a clear estimate for the IQVIA matters.
- The impact of the CEO’s planned option exercise and share sales or donations, including related payroll taxes and tax-rate effects.
- Changes in investment-portfolio unrealized losses, operating cash flow, and the effects of interest-rate movements on liquidity and comprehensive income.